Liu P - Search Results

1

mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR.

Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis CA, Gygi SP, Toker A, Cantley LC, Asara JM, Harper JW, Wei W. Gao D, et al. Among authors: liu p. Mol Cell. 2011 Oct 21;44(2):290-303. doi: 10.1016/j.molcel.2011.08.030. Mol Cell. 2011. PMID: 22017875 Free PMC article.

2

Mcl-1 ubiquitination and destruction.

Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Inuzuka H, et al. Among authors: liu p. Oncotarget. 2011 Mar;2(3):239-44. doi: 10.18632/oncotarget.242. Oncotarget. 2011. PMID: 21608150 Free PMC article. Review.

3

Skp2: a novel potential therapeutic target for prostate cancer.

Wang Z, Gao D, Fukushima H, Inuzuka H, Liu P, Wan L, Sarkar FH, Wei W. Wang Z, et al. Among authors: liu p. Biochim Biophys Acta. 2012 Jan;1825(1):11-7. doi: 10.1016/j.bbcan.2011.09.002. Epub 2011 Sep 22. Biochim Biophys Acta. 2012. PMID: 21963805 Free PMC article. Review.

4

The two faces of FBW7 in cancer drug resistance.

Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L, Lau AW, Liu P, Wei W. Wang Z, et al. Among authors: liu p. Bioessays. 2011 Nov;33(11):851-9. doi: 10.1002/bies.201100101. Epub 2011 Aug 30. Bioessays. 2011. PMID: 22006825 Free PMC article. Review.

5

Skp2 is a promising therapeutic target in breast cancer.

Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W. Wang Z, et al. Among authors: liu p. Front Oncol. 2012 Jan 4;1(57):57. doi: 10.3389/fonc.2011.00057. Front Oncol. 2012. PMID: 22279619 Free PMC article.

6

DEPTOR ubiquitination and destruction by SCF(β-TrCP).

Wang Z, Zhong J, Gao D, Inuzuka H, Liu P, Wei W. Wang Z, et al. Among authors: liu p. Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E163-9. doi: 10.1152/ajpendo.00105.2012. Epub 2012 Mar 27. Am J Physiol Endocrinol Metab. 2012. PMID: 22454292 Free PMC article. Review.

7

DNA damage-induced activation of ATM promotes β-TRCP-mediated Mdm2 ubiquitination and destruction.

Wang Z, Inuzuka H, Zhong J, Fukushima H, Wan L, Liu P, Wei W. Wang Z, et al. Among authors: liu p. Oncotarget. 2012 Sep;3(9):1026-35. doi: 10.18632/oncotarget.640. Oncotarget. 2012. PMID: 22976441 Free PMC article.

8

Cdc20: a potential novel therapeutic target for cancer treatment.

Wang Z, Wan L, Zhong J, Inuzuka H, Liu P, Sarkar FH, Wei W. Wang Z, et al. Among authors: liu p. Curr Pharm Des. 2013;19(18):3210-4. doi: 10.2174/1381612811319180005. Curr Pharm Des. 2013. PMID: 23151139 Free PMC article. Review.

9

Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2.

Wang Z, Inuzuka H, Zhong J, Liu P, Sarkar FH, Sun Y, Wei W. Wang Z, et al. Among authors: liu p. Oncotarget. 2012 Nov;3(11):1294-300. doi: 10.18632/oncotarget.740. Oncotarget. 2012. PMID: 23230084 Free PMC article.

10

Regulation of APC(Cdh1) E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7.

Lau AW, Inuzuka H, Fukushima H, Wan L, Liu P, Gao D, Sun Y, Wei W. Lau AW, et al. Among authors: liu p. Cell Res. 2013 Jul;23(7):947-61. doi: 10.1038/cr.2013.67. Epub 2013 May 14. Cell Res. 2013. PMID: 23670162 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25,691 results

Search Page

Filters